Special Issue

Molecular Mechanisms of Coronary Disease

Message from the Guest Editors

Coronary artery disease (CAD) is predicted to continue as the worldwide leading cause of human mortality for at least the next two decades. Epidemiological and genome-wide studies have revealed hundreds of important environmental and genetic risk factors associated with CAD. Progress in defining the molecular mechanisms involved, however, has been hindered by the disease's complexity. Over the past decade, the availability of new technologies, such as single-cell sequencing, multi-omics approaches, and CRISPR-modified mouse models, has resulted in a clearer understanding of the development of atherosclerotic plaque. This Special Issue focuses on molecular mechanisms (cell fate transition and vascular remodeling, transcriptional and epigenetic regulations in the plaque, cytokines and signaling pathways, genetic risk factors, calcification, etc.) of CAD, aiming to improve our knowledge of the disease and provide insights for personalized medicine.

Guest Editors

Dr. Quanyi Zhao

Division of Cardiovascular Medicine and Cardiovascular Institute, School of Medicine, Stanford University, 300 Pasteur Drive, Falk CVRC, Stanford, CA 94305, USA

Dr. João P. Monteiro

School of Medicine, Stanford University, Stanford, CA, USA

Deadline for manuscript submissions

28 February 2026

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/249308

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).